Jaknat (tofacitinib) tablets is a prescription medicine. Jaknat (tofacitinib) tablets is used to treat adults with moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated.
INDICATIONS AND USAGE
Jaknat (tofacitinib) is a Janus kinase (JAK) inhibitor.
- Rheumatoid Arthritis: XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
- Psoriatic Arthritis: XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other.
- Ulcerative Colitis: XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
DOSAGE FORMS & STRENGTHS
Jaknat Tablets: 5 mg
Manufactured By: Pfizer
Prescribing Information URL: Click Here
South Delhi Pharma facilitate the supply of “XELJANZ XR (tofacitinib) tablets FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Tofacitinib, sold under the brand Jaknat among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is in the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer. Tofacitinib is a small molecule, not a biologic.
- Rheumatoid arthritis
Tofacitinib citrate is approved for medical use in the United States with an indication "to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate." In the European Union, in combination with methotrexate, tofacitinib citrate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults...
- Ulcerative colitis
In May 2018, the FDA approved tofacitinib citrate "for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis." Tofacitinib citrate is the first oral JAK inhibitor approved for chronic use in ulcerative colitis.